Unit
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
[Adjuvant therapy with trastuzumab in primary breast neoplasms--findings and validity of--opinion on the competence of the Central Oncology section of the North German Society]
Huober J. [Adjuvant therapy with trastuzumab in primary breast neoplasms--findings and validity of--opinion on the competence of the Central Oncology section of the North German Society]. Zentralbl Gynakol 2006; 128:187; author reply 187-8.
Jun 1, 2006[Adjuvant therapy with trastuzumab in primary breast neoplasms--findings and validity of--opinion on the competence of the Central Oncology section of the North German Society]
Jun 1, 2006Zentralbl Gynakol 2006; 128:187; author reply 187-8
Huober Jens
Palliative in-patient cancer treatment in an anthroposophic hospital: II. Quality of life during and after stationary treatment, and subjective treatment benefits
Heusser P, Braun S, Bertschy M, Burkhard R, Ziegler R, Helwig S, van Wegberg B, Cerny T. Palliative in-patient cancer treatment in an anthroposophic hospital: II. Quality of life during and after stationary treatment, and subjective treatment benefits. Forschende Komplementärmedizin (2006) 2006; 13:156-66.
Jun 1, 2006Palliative in-patient cancer treatment in an anthroposophic hospital: II. Quality of life during and after stationary treatment, and subjective treatment benefits
Jun 1, 2006Forschende Komplementärmedizin (2006) 2006; 13:156-66
Heusser Peter, Braun Sarah Berger, Bertschy Manuel, Burkhard René, Ziegler Renatus, Helwig Silke, van Wegberg Brigitte, Cerny Thomas
Ein Heilmittel namens Spiritualität?
Renz M. Ein Heilmittel namens Spiritualität? - Vom Versuch die therapeutische Wirkung immaterieller Kräfte zu quantifizieren. Neue Zürcher Zeitung 2006; 6. Mai:75.
May 6, 2006Ein Heilmittel namens Spiritualität?
May 6, 2006Neue Zürcher Zeitung 2006; 6. Mai:75
Renz Monika
Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment
Glaus A, Böhme C, Thürlimann B, Ruhstaller T, Hsu Schmitz S, Morant R, Senn H, von Moos R. Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment. Ann Oncol 2006; 17:801-6.
May 1, 2006Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment
May 1, 2006Ann Oncol 2006; 17:801-6
Glaus A, Böhme Christel, Thürlimann Beat, Ruhstaller Thomas, Hsu Schmitz S F, Morant R, Senn H J, von Moos R
An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma
Hartmann J, Oechsle K, Huober J, Jakob A, Azemar M, Horger M, Kanz L, Bokemeyer C. An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma. Investigational new drugs 2006; 24:249-53.
May 1, 2006An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma
May 1, 2006Investigational new drugs 2006; 24:249-53
Hartmann J T, Oechsle K, Huober Jens, Jakob A, Azemar M, Horger M, Kanz L, Bokemeyer C
Expression of MAGE-A cancer/testis antigens in esophageal squamous cell carcinomas
Haier J, Owzcareck M, Gueller U, Spagnoli G, Bürger H, Senninger N, Kocher T. Expression of MAGE-A cancer/testis antigens in esophageal squamous cell carcinomas. Anticancer Res 2006; 26:2281-7.
May 1, 2006Expression of MAGE-A cancer/testis antigens in esophageal squamous cell carcinomas
May 1, 2006Anticancer Res 2006; 26:2281-7
Haier J, Owzcareck M, Gueller Ulrich, Spagnoli G C, Bürger H, Senninger N, Kocher Th
Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study
Betticher D, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny T, Ris H, Stahel R, Spiliopoulos A, Roth A, Hsu Schmitz S, Tötsch M, Hansen E, Joss C, von Briel C, Schmid R, Pless M, Habicht J, Swiss Group for Clinical Cancer Research (SAKK). Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. British journal of cancer 2006; 94:1099-106.
Apr 24, 2006Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study
Apr 24, 2006British journal of cancer 2006; 94:1099-106
Betticher D C, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny Thomas, Ris H-B, Stahel R, Spiliopoulos A, Roth A D, Hsu Schmitz S-F, Tötsch M, Hansen E, Joss C, von Briel C, Schmid R A, Pless M, Habicht J, Swiss Group for Clinical Cancer Research (SAKK)
A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma
Jermann M, Bauer J, Rhyner K, Egli F, Morant R, Gillessen Sommer S, Jörger M, Cerny T, Salzberg M, Stahel R, Pless M. A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma. Cancer chemotherapy and pharmacology 2006; 57:533-9.
Apr 1, 2006A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma
Apr 1, 2006Cancer chemotherapy and pharmacology 2006; 57:533-9
Jermann Monika, Bauer Jean A, Rhyner Kaspar, Egli Fritz, Morant Rudolf, Gillessen Sommer Silke, Jörger Markus, Cerny Thomas, Salzberg Marc, Stahel Rolf A, Pless Miklos
Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors
Jörger M, Huitema A, van den Bongard D, Schellens J, Beijnen J. Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 2006; 12:2150-7.
Apr 1, 2006Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors
Apr 1, 2006Clinical cancer research : an official journal of the American Association for Cancer Research 2006; 12:2150-7
Jörger Markus, Huitema Alwin D R, van den Bongard Desiree H J G, Schellens Jan H M, Beijnen Jos H
[The plasma cell myeloma--molecular pathogenesis and target therapies]
Hess U. [The plasma cell myeloma--molecular pathogenesis and target therapies]. Ther Umsch 2006; 63:233-6.
Apr 1, 2006[The plasma cell myeloma--molecular pathogenesis and target therapies]
Apr 1, 2006Ther Umsch 2006; 63:233-6
Hess Urs
Palliative in-patient cancer treatment in an anthroposophic hospital: I. Treatment patterns and compliance with anthroposophic medicine
Heusser P, Braun S, Ziegler R, Bertschy M, Helwig S, van Wegberg B, Cerny T. Palliative in-patient cancer treatment in an anthroposophic hospital: I. Treatment patterns and compliance with anthroposophic medicine. Forschende Komplementärmedizin (2006) 2006; 13:94-100.
Apr 1, 2006Palliative in-patient cancer treatment in an anthroposophic hospital: I. Treatment patterns and compliance with anthroposophic medicine
Apr 1, 2006Forschende Komplementärmedizin (2006) 2006; 13:94-100
Heusser Peter, Braun Sarah Berger, Ziegler Renatus, Bertschy Manuel, Helwig Silke, van Wegberg Brigitte, Cerny Thomas
Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas
Leyvraz S, Honegger H, Dietrich D, Fey M, Sessa C, Cerny T, Lissoni A, Jundt G, Zweifel M, Swiss Group for Clinical Cancer Research. Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006; 17:646-51.
Apr 1, 2006Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas
Apr 1, 2006Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006; 17:646-51
Leyvraz S, Honegger H P, Dietrich D, Fey M, Sessa C, Cerny Thomas, Lissoni A, Jundt G, Zweifel M, Swiss Group for Clinical Cancer Research
A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC)
Kollmannsberger C, Schittenhelm M, Honecker F, Tillner J, Weber D, Oechsle K, Kanz L, Bokemeyer C. A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2006; 17:1007-13.
Mar 13, 2006A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC)
Mar 13, 2006Ann Oncol 2006; 17:1007-13
Kollmannsberger C, Schittenhelm Marcus, Honecker F, Tillner J, Weber D, Oechsle K, Kanz L, Bokemeyer C
Surgical outcomes research based on administrative data: inferior or complementary to prospective randomized clinical trials?
Gueller U. Surgical outcomes research based on administrative data: inferior or complementary to prospective randomized clinical trials?. World J Surg 2006; 30:255-66.
Mar 1, 2006Surgical outcomes research based on administrative data: inferior or complementary to prospective randomized clinical trials?
Mar 1, 2006World J Surg 2006; 30:255-66
Gueller Ulrich
Carbon dye staining of sentinel lymph nodes facilitates microstaging of colon cancer patients
Viehl C, Gueller U, Hamel C, Riehle H, Plaass C, Marti W, Oertli D, Zuber M. Carbon dye staining of sentinel lymph nodes facilitates microstaging of colon cancer patients. World J Surg 2006; 30:453-6.
Mar 1, 2006Carbon dye staining of sentinel lymph nodes facilitates microstaging of colon cancer patients
Mar 1, 2006World J Surg 2006; 30:453-6
Viehl Carsten T, Gueller Ulrich, Hamel Christian T, Riehle Hans-Martin, Plaass Christian, Marti Walter R, Oertli Daniel, Zuber Markus
Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer
Fürstenberger G, von Moos R, Lucas R, Thürlimann B, Senn H, Hamacher J, Boneberg E. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. BJC 2006; 94:524-31.
Feb 27, 2006Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer
Feb 27, 2006BJC 2006; 94:524-31
Fürstenberger G, von Moos R, Lucas R, Thürlimann Beat, Senn H-J, Hamacher J, Boneberg E-M
[Treatment possibilities for patients with advanced prostate cancer]
Gillessen Sommer S, Strasser F. [Treatment possibilities for patients with advanced prostate cancer]. Therapeutische Umschau. Revue thérapeutique 2006; 63:157-62.
Feb 1, 2006[Treatment possibilities for patients with advanced prostate cancer]
Feb 1, 2006Therapeutische Umschau. Revue thérapeutique 2006; 63:157-62
Gillessen Sommer Silke, Strasser Florian
[Adjuvant therapy with trastuzumab (Herceptin) in primary breast cancer]
Huober J, Jackisch C, Untch M, Möbus V, Wallwiener D, Kaufmann M, Minkwitz G. [Adjuvant therapy with trastuzumab (Herceptin) in primary breast cancer]. Zentralblatt für Gynäkologie 2006; 128:30-7.
Feb 1, 2006[Adjuvant therapy with trastuzumab (Herceptin) in primary breast cancer]
Feb 1, 2006Zentralblatt für Gynäkologie 2006; 128:30-7
Huober Jens, Jackisch C, Untch M, Möbus V, Wallwiener D, Kaufmann M, Minkwitz G
Platelet count and function at high altitude and in high-altitude pulmonary edema.
Lehmann T, Mairbäurl H, Pleisch B, Maggiorini M, Bärtsch P, Reinhart W. Platelet count and function at high altitude and in high-altitude pulmonary edema. J Appl Physiol (1985) 2006; 100:690-4.
Feb 1, 2006Platelet count and function at high altitude and in high-altitude pulmonary edema.
Feb 1, 2006J Appl Physiol (1985) 2006; 100:690-4
Lehmann Thomas, Mairbäurl Heimo, Pleisch B, Maggiorini M, Bärtsch P, Reinhart W H
Combination chemotherapy with carboplatin, capecitabine and epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer: a phase I/II trial
Rothermundt C, Hubner R, Ahmad T, Gibbens I, Keyzor C, Habeshaw T, Kaye S, Gore M. Combination chemotherapy with carboplatin, capecitabine and epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer: a phase I/II trial. British journal of cancer 2006; 94:74-8.
Jan 16, 2006Combination chemotherapy with carboplatin, capecitabine and epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer: a phase I/II trial
Jan 16, 2006British journal of cancer 2006; 94:74-8
Rothermundt Christian, Hubner R, Ahmad T, Gibbens I, Keyzor C, Habeshaw T, Kaye S, Gore M